Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

News

Banner

Shorla Oncology attending JP Morgan Healthcare Conference

December 8th 2023

Read More

Rayna

Press Release: Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer

December 8th 2023

Read More

Banner

Shorla Oncology at ASH Annual Meeting and Exposition

November 21st 2023

Read More

Banner

Shorla Oncology attending Jefferies Healthcare Conference

October 31st 2023

Read More

Logo

PRESS RELEASE: Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind

October 31st 2023

Read More

Logo

Goodman-backed Shorla Oncology secures $35m in Series-B funding

October 24th 2023

Read More

Logo

Shorla Oncology raises $35m to accelerate growth

October 24th 2023

Read More

Photo

Raising Funds in a Tight Market: Q&A With Sharon Cunningham, CEO of Shorla Oncology

October 24th 2023

Read More

Logo

Shorla Oncology at BIO-Europe 2023

October 20th 2023

Read More

Older posts
Newer posts
Page1 … Page8 Page9 Page10 … Page19
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.